BTHE Insider Trading Activity and SEC Form 4 Filings
BTHE insider trading summary
No open-market insider purchases or sales of Boston Therapeutics, Inc. (BTHE) have been reported on SEC Form 4 in the past 12 months.
Latest BTHE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 15, 2015 | Dale H Conaway | Director | Buy | $600 (5,000 @ $0.12) |
| May 15, 2015 | David Platt | CEO and Chairman | Buy | $148 (1,000 @ $0.15) |
| May 14, 2015 | David Platt | CEO and Chairman | Buy | $600 (5,000 @ $0.12) |
| Mar 18, 2015 | Henry Jemil Esber | Director | Buy | $2K (9,000 @ $0.20) |
| Mar 10, 2015 | Anthony Don Squeglia | Chief Financial Officer | Buy | $2K (10,000 @ $0.22) |
| Mar 10, 2015 | Alan M Hoberman | Director | Buy | $1K (5,000 @ $0.22) |
| Mar 9, 2015 | David Platt | CEO and Chairman | Buy | $112 (465 @ $0.24) |
| Mar 9, 2015 | David Platt | CEO and Chairman | Buy | $526 (2,285 @ $0.23) |
| Mar 9, 2015 | David Platt | CEO and Chairman | Buy | $630 (3,000 @ $0.21) |
| Mar 9, 2015 | David Platt | CEO and Chairman | Buy | $306 (1,250 @ $0.24) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.